Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06070012 · ClinicalTrials.gov registry record · Phase 2
Tebentafusp in HLA-A*0201 Positive Previously Untreated Metastatic Uveal Melanoma
A Phase 2 study of Uveal Melanoma, sponsored by Diwakar Davar.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 44
- Enrollment target
- 3
- Study locations
NCT06070012: Recruiting Phase 2 study of Uveal Melanoma, sponsored by Diwakar Davar.
NCT06070012 is a Phase 2 study of Uveal Melanoma that is actively recruiting participants, run by Diwakar Davar. The registered enrollment target is 44 participants, below the 144-participant average among 29 other Uveal Melanoma trials with a reported enrollment target (69% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06070012, a Phase 2 study of Uveal Melanoma, is actively recruiting participants, sponsored by Diwakar Davar.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 44 participants
- Enrollment target
- 3
- Study locations
Study Summary
This is a phase II open-label, single-arm, multi-center study of tebentafusp in HLA- A\*0201 positive previously untreated (1L) untreated metastatic uveal melanoma (mUM) with an integrated circulating tumor DNA (ctDNA) biomarker.
Primary Outcome
ctDNA response (defined as ≥0.3 log reduction) in ctDNA-evaluable patients as measured using Signatera assay.
Conditions Studied
Interventions
- DRUG Tebentafusp
Study Locations (3)
Colorado
- University of Colorado Cancer Center - Aurora
District of Columbia
- Georgetown University Medical Center - Washington D.C.
Pennsylvania
- UPMC Hillman Cancer Center - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 2025-08-18 |
| Est. Completion | 2030-09-30 |
| Phase | Phase 2 |
What NCT06070012 shows while recruiting
NCT06070012 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 44 participants, a relatively small participant target, below the 144-participant average among 29 other Uveal Melanoma trials with a reported enrollment target (69% lower).
The record links to 1 condition, with Uveal Melanoma appearing as the primary indexed condition, and to 1 intervention - of which Tebentafusp is the first listed.
NCT06070012 reports a single indexed study location in Colorado, District of Columbia, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT06070012 about?
NCT06070012 is a clinical study titled "Tebentafusp in HLA-A*0201 Positive Previously Untreated Metastatic Uveal Melanoma". This is a phase II open-label, single-arm, multi-center study of tebentafusp in HLA- A\*0201 positive previously untreated (1L) untreated metastatic uveal melanoma (mUM) with an integrated circulating tumor DNA (ctDNA) biomarker.
What is the current status of trial NCT06070012?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 44 participants. The study started on 2025-08-18. Estimated completion is 2030-09-30.
What conditions does trial NCT06070012 study?
This clinical trial studies the following conditions: Uveal Melanoma.
What interventions are being tested in trial NCT06070012?
The interventions under investigation include: Tebentafusp (DRUG).
Who is sponsoring clinical trial NCT06070012?
This trial is sponsored by Diwakar Davar, which has 12 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06070012 being conducted?
This trial has 3 study locations across Colorado, District of Columbia, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Uveal Melanoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06070012's enrollment target sits among peer trials
44 16th of 29 higher than 14 of 29 other Uveal Melanoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Uveal Melanoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of Concurrent Stereotactic Body Radiotherapy With Opdualag in Metastatic Uveal Melanoma
RECRUITING · Phase 2
-
Olaparib in Combination With Pembrolizumab for Advanced Uveal Melanoma
RECRUITING · Phase 2
-
Adjuvant Quisinostat in High-Risk Uveal Melanoma
RECRUITING · Phase 2
-
Diet and Immune Effects Trial: DIET- A Randomized Double Blinded Dietary Intervention Study in Patients With Metastatic Melanoma Receiving Immunotherapy
ACTIVE NOT RECRUITING · Phase 2
-
(Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma
ACTIVE NOT RECRUITING · Phase 2
-
Crizotinib in High-Risk Uveal Melanoma Following Definitive Therapy
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02323945 · 44 participants · NA
Effects of Breathing Mild Bouts of Low Oxygen on Limb Mobility After Spinal Injury
- NCT03093909 · 44 participants · Phase 1
Study of Aerosol Gemcitabine in Patients With Solid Tumors and Pulmonary Metastases
- NCT03104491 · 44 participants · Phase 1
Inotuzumab Ozogamicin Post-Transplant For Acute Lymphocytic Leukemia
- NCT03781765 · 44 participants · Phase 4
Stimulant vs. Non-stimulant Treatments and Reward Processing in Drug-naive Youth at SUD Risk
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI